Wall Street Zen Upgrades Claritev (NYSE:CTEV) to Hold

Key Points

• Wall Street Zen upgraded Claritev from “sell” to “hold,” while analysts remain divided; the consensus rating is “Hold” with an average price target of $34.50.
• Claritev opened at $32.00, with shares trading between a 52-week range of $11.50 to $74.07. Institutional investors own approximately 87.15% of the company.
• Recent business results were favorable, including 6.6% year-over-year revenue growth to about $257.5 million, stronger operating and free cash flow, and higher 2026 revenue and adjusted EBITDA guidance.

Claritev (NYSE:CTEV - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Several other equities research analysts have also weighed in on CTEV. Citigroup restated a "buy" rating on shares of Claritev in a research report on Wednesday, May 13th. Zacks Research downgraded Claritev from a "hold" rating to a "strong sell" rating in a report on Friday, July 17th. Canaccord Genuity Group raised their price objective on Claritev from $32.00 to $37.00 and gave the company a "buy" rating in a research report on Tuesday, July 21st. Weiss Ratings restated a "sell (d-)" rating on shares of Claritev in a report on Wednesday, June 24th. Finally, Barclays began coverage on shares of Claritev in a report on Friday, April 24th. They set an "overweight" rating and a $28.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $34.50.

Claritev Stock Performance

Claritev stock opened at $32.00 on Friday. Claritev has a fifty-two week low of $11.50 and a fifty-two week high of $74.07. The stock's 50 day simple moving average is $28.88 and its two-hundred day simple moving average is $23.79. The stock has a market cap of $545.60 million, a price-to-earnings ratio of -1.85 and a beta of 0.74.

Institutional Investors Weigh In On Claritev

A number of institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. purchased a new position in shares of Claritev in the 3rd quarter worth about $1,245,000. Vanguard Group Inc. bought a new position in Claritev in the 3rd quarter worth about $27,483,000. Ameritas Investment Partners Inc. purchased a new stake in Claritev during the 3rd quarter valued at about $42,000. Russell Investments Group Ltd. purchased a new stake in Claritev during the 3rd quarter valued at about $369,000. Finally, Legal & General Group Plc bought a new stake in Claritev during the 3rd quarter valued at about $45,000. 87.15% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Claritev

Here are the key news stories impacting Claritev this week:

• Positive Sentiment: Better-than-expected quarterly performance: Claritev reported Q2 revenue of approximately $257.5 million, up 6.6% year over year. The company’s net loss narrowed to $59.2 million from $62.6 million, while adjusted EBITDA reached $155.8 million. Reported earnings also surpassed the consensus loss estimate, although published sources show differing EPS figures depending on the accounting presentation. Claritev Corporation Reports Second Quarter 2026 Results Claritev Reports Q2 Loss and Tops Revenue Estimates
• Positive Sentiment: Raised 2026 guidance: Management now expects full-year revenue of $1.0 billion to $1.02 billion and adjusted EBITDA of $610 million to $620 million. The revenue outlook is above the roughly $994.7 million analyst consensus, signaling confidence in continued operating momentum. Claritev Beats Second-Quarter Expectations and Raises Guidance
• Positive Sentiment: Improved cash generation: Operating cash flow increased to $92.7 million from $61.2 million a year earlier, while free cash flow rose to $54.6 million from $36.6 million. The gains provide additional support for the company’s financial flexibility. Claritev Q2 Revenue Rises 6.6 Percent
• Positive Sentiment: Favorable trading sentiment: Investor commentary focused on the earnings beat, higher guidance and increased trading volume. Six reported insider transactions over the past six months were purchases, with no reported sales, though insider activity is not a guarantee of future performance. Claritev Stock Opinions on Q2 Earnings Beat

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source